Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Azulfidine EN, Azulfidine
Synonyms :
Class :
5-Aminosalicylates and DMARDs
Brand Name :
Azulfidine EN, Azulfidine
Synonyms :
Class :
5-Aminosalicylates and DMARDs
Dosage Forms & Strengths Â
Tablet Â
500mg Â
Tablet, enteric coated (delayed release) Â
500mg Â
Initial: 3-4 g/day orally divided three times a day
Do not exceed more than 4g a day leads to increased risk of toxicity
Maintenance: 2 g/day in divided doses every 8 hours
0.5-1 g/day delayed release orally divided 2x; increase weekly 2 g/day 2x; if response inadequate, may increase to 3 g/day
(Off-label)
3-6 g/day orally divided doses for up to 16 weeks
Dosage Forms & Strengths Â
Tablet Â
500mg Â
Tablet-enteric-coated (delayed release) Â
500 mg Â
measles, mumps, rubella, and varicella vaccine, live (Rx)
may enhance the adverse/toxic effect of varicella virus-containing vaccines
measles mumps and rubella vaccine, live
may enhance the adverse/toxic effect of varicella virus-containing vaccines
may enhance the adverse/toxic effect of varicella virus-containing vaccines
vaccinia immune globulin intravenous (Rx)
may enhance the adverse/toxic effect of varicella virus-containing vaccines
may enhance the adverse/toxic effect of varicella virus-containing vaccines
measles, mumps, rubella and varicella vaccine, liveÂ
may increase the toxic effects of varicella virus containing vaccine
may decrease the therapeutic effect of COVID-19 vaccine
may increase the anticoagulation effect when combined
may increase the toxic effect of 5-aminosalicylic Acid Derivatives
interaction with NSAIDs may lead to increased toxicity such as myelosuppression, renal toxicity, and GI toxicity
interaction with NSAIDs may lead to increased toxicity such as myelosuppression, renal toxicity, and GI toxicity
ciprofloxacin inhaled (Pending FDA approval)Â
may enhance the photosensitizing effect of photosensitizing agents
NSAIDs may increase the nephrotoxic effect of 5-aminosalicylic acid derivatives
NSAIDs may increase the nephrotoxic effect of 5-aminosalicylic acid derivatives
NSAIDs may increase the nephrotoxic effect of 5-aminosalicylic acid derivatives
NSAIDs may increase the nephrotoxic effect of 5-aminosalicylic acid derivatives
NSAIDs may increase the nephrotoxic effect of 5-aminosalicylic acid derivatives
may enhance the effect of myelosuppressive agents
may enhance the effect of myelosuppressive agents
may enhance the effect of myelosuppressive agents
may enhance the effect of myelosuppressive agents
may enhance the effect of myelosuppressive agents
may have an increased myelosuppressive effect when combined with myelosuppressive agents
5-Aminosalicylic Acid Derivatives: they may diminish the serum concentration of cardiac glycosides
5-Aminosalicylic Acid Derivatives: they may diminish the serum concentration of cardiac glycosides
5-Aminosalicylic Acid Derivatives: they may diminish the serum concentration of cardiac glycosides
5-Aminosalicylic Acid Derivatives: they may increase the anticoagulant effect of Vitamin K Antagonists
5-Aminosalicylic Acid Derivatives: they may increase the anticoagulant effect of Vitamin K Antagonists
5-Aminosalicylic Acid Derivatives: they may increase the anticoagulant effect of Vitamin K Antagonists
5-Aminosalicylic Acid Derivatives: they may increase the anticoagulant effect of Vitamin K Antagonists
5-Aminosalicylic Acid Derivatives: they may increase the anticoagulant effect of Vitamin K Antagonists
It may enhance the effect when combined with tafamidis meglumine
5-Aminosalicylic Acid Derivatives: they may increase the myelosuppressive effect of myelosuppressive agents
When loracarbef is used together with sulfasalazine, the risk or seriousness of nephrotoxicity is enhanced
When bufexamac is used together with sulfasalazine, this leads to a reduction in therapeutic effectiveness of sulfasalazine
may have an increased nephrotoxic effect when combined with 5-aminosalicylic acid
hepatitis A vaccine inactivatedÂ
combining sulfasalazine with the Hepatitis A Vaccine may reduce its therapeutic efficiency
may have an increased nephrotoxic effect when combined with 5-aminosalicylic acid
may enhance hepatotoxic adverse effects of methotrexate
may enhance hepatotoxic adverse effects of trimetrexate
lansoprazole amoxicillin and clarithromycin
when amoxicillin combines with sulfasalazine it decreases the effects of action of drug by plasma binding protein and results in lowering of renal clearance
amoxicillin and clavulanate potassium
when amoxicillin combines with sulfasalazine it decreases the effects of action of drug by plasma binding protein and results in lowering of renal clearance
omeprazole amoxicillin and clarithromycin
when both drugs are combined, the drug's action may decrease the effect of decreasing renal clearance
when both drugs are combined, the drug's action may decrease the effect of decreasing renal clearance
may increase the myelosuppressive effect
may increase the myelosuppressive effect of myelosuppressive agents
may enhance the nephrotoxic effect of 5-Aminosalicylic Acid Derivatives
may enhance the nephrotoxic effect of 5-Aminosalicylic Acid Derivatives
may enhance the nephrotoxic effect of 5-Aminosalicylic Acid Derivatives
may enhance the nephrotoxic effect of 5-Aminosalicylic Acid Derivatives
may enhance the nephrotoxic effect of 5-Aminosalicylic Acid Derivatives
may increase the nephrotoxic effect of non-steroidal anti-inflammatory drugs
may increase the myelosuppressive effect of myelosuppressive agents
may enhance the risk or severity of hypertension when combined
may increase the risk or severity of toxic effects when combined
may increase the myelosuppressive effect of myelosuppressive agents
may increase the myelosuppressive effect of myelosuppressive agents
may increase the myelosuppressive effect of myelosuppressive agents
may increase the nephrotoxic effect of nonsteroidal anti-inflammatory agents
may increase the myelosuppressive effect of thiopurine analogs
may increase the myelosuppressive effect of myelosuppressive agents
may increase the myelosuppressive effect of Myelosuppressive Agents
may increase the myelosuppressive effect of Myelosuppressive Agents
may increase the Myelosuppressive effect of Myelosuppressive Agents
bacitracin, when combined with sulfasalazine, is serious and risky, leading to nephrotoxicity
may diminish the serum concentration of 5-Aminosalicylic Acid Derivatives
may diminish the serum concentration of 5-Aminosalicylic Acid Derivatives
may diminish the serum concentration of 5-Aminosalicylic Acid Derivatives
may have an increased nephrotoxic effect when combined with 5-aminosalicylic acid
when both drugs are combined, there may be an increased effect of sulfasalazine by acidic drug competition for renal tubular clearance  
cefprozil will increase the effects of sulfasalazine
cefaclor will increase the effects of sulfasalazine
cefepime will increase the effects of sulfasalazine
cefuroxime will increase the effects of sulfasalazine
Adverse drug reactions:  Â
 Frequency Defined Â
>10% Â
Anorexia Â
Vomiting  Â
Gastric distress Â
Headache Â
Nausea Â
<1% Â
Pruritus Â
Urticaria Â
Skin rash Â
Fever Â
Hemolytic anemia Â
Cyanosis Â
Heinz body anemia Â
Post marketing Reports Â
Myocarditis Â
Pseudo mononucleosis Â
Â
Â
Pregnancy warnings:    Â
AU TGA pregnancy category: AÂ
US FDA pregnancy category: BÂ
Lactation:Â
Excreted into human milk is unknownÂ
Pregnancy Categories:      Â
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first or later trimester.      Â
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women      Â
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women      Â
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.      Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.      Â
Category N: There is no data available for the drug under this categoryÂ
Patient Information Leaflet   Â
Generic Name: sulfasalazine (Rx)Â
Why do we use sulfasalazine (Rx)? Â
sulfasalazine (Rx)is a 5-Aminosalicylic Acid Derivatives; DMARDs used to treat Ulcerative Colitis, Rheumatoid Arthritis, and Crohn Disease.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
